Skip to main content
Privia Health Group Inc. (PRVA)
Computer Software and Services Information Technology
Stock AI

Privia Health Group Inc. Reports Strong Financial Results for 2024

Last updated: February 27, 2025
Taurigo

Privia Health Group, Inc. (Nasdaq: PRVA) announced its financial and operational results for the fourth quarter and full year ended December 31, 2024. The company reported performance metrics that exceeded the high end of its guidance ranges for 2024, showcasing robust growth and operational efficiency.

1. Full-Year Financial Performance

Privia Health achieved total revenue of $1.736 billion for the year, marking a 4.7% increase from $1.658 billion in 2023. This growth was accompanied by a gross profit of $397.7 million, up 12.4% from the previous year's $353.8 million. Despite these gains, the company saw a decline in operating income, which fell 17.8% to $17 million, compared to $20.6 million in 2023.

Key Financial Metrics

Metric FY 2024 FY 2023 Change (%)
Total Revenue $1,736.4 million $1,657.7 million +4.7%
Gross Profit $397.7 million $353.8 million +12.4%
Operating Income $17.0 million $20.6 million -17.8%
Net Income $14.4 million $23.1 million -37.7%
Non-GAAP Adjusted Net Income $97.6 million $81.5 million +19.8%

Net income for full-year 2024 was significantly impacted by non-cash stock compensation and legal expenses, amounting to $56.7 million and $9.5 million, respectively. This resulted in a net income per share of $0.11, down 42.1% from $0.19 in 2023. However, the non-GAAP adjusted net income per share improved by 21.9%, reaching $0.78, up from $0.64 the previous year.

2. Fourth Quarter Highlights

For the fourth quarter of 2024, Privia Health reported total revenue of $460.9 million, a 4.6% increase from $440.8 million in the same quarter of 2023. The company recorded a gross profit of $106.1 million, an 18% increase year-over-year. Operating income surged 269.6% to $5.2 million, and net income rose 55% to $4.4 million compared to $2.8 million in Q4 2023.

Fourth Quarter Key Metrics

Metric Q4 2024 Q4 2023 Change (%)
Total Revenue $460.9 million $440.8 million +4.6%
Gross Profit $106.1 million $90.0 million +18.0%
Operating Income $5.2 million $1.4 million +269.6%
Net Income $4.4 million $2.8 million +55.0%
Non-GAAP Adjusted Net Income $26.5 million $20.3 million +30.5%

3. Operational Highlights

Privia Health noted several significant operational achievements in 2024:

  • Provider Signings: Implemented providers increased by 11.2% to 4,789.
  • Collections Growth: Fee-for-service collections grew 13.6% year-over-year, with practice collections totaling $2.968 billion.
  • Value-Based Care Success: The company achieved shared savings of $176.6 million through the Medicare Shared Savings Program, a 34.1% increase from 2022.
  • Adjusted EBITDA: Grew 25.2% over the previous year, reflecting improved operational efficiency.

4. Capital Resources and Cash Flow

As of December 31, 2024, Privia Health's balance sheet showed a strong position with $491.1 million in cash and cash equivalents and no debt, compared to $389.5 million and no debt at the end of 2023. The company generated $109.3 million in net cash from operating activities, a 35.3% increase from 2023.

5. 2025 Outlook

Looking ahead to 2025, Privia Health aims to enhance its operating leverage and increase density and scale in existing states through organic growth. The company is targeting a conversion of at least 80% of adjusted EBITDA to free cash flow while pursuing new business development opportunities in both existing and new markets.

2025 Guidance

Privia Health provided the following guidance for 2025:

Metric FY 2025 Guidance (Low) FY 2025 Guidance (High) Y-Y % Change (Low) Y-Y % Change (High)
Implemented Providers 5,200 5,300 +8.6% +10.7%
Attributed Lives 1,300,000 1,400,000 +3.5% +11.5%
GAAP Revenue $1,800 million $1,900 million +3.7% +9.4%

Overall, Privia Health's strong performance in 2024 and optimistic outlook for 2025 reflect its commitment to growth in the evolving healthcare landscape.

You may also be interested in:
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.